Clinical study in Parkinson's disease with two unique goals: 1) Proof-of-concept of CDNF protein for disease modification; 2) Validation of clinically tested device for intracerebral drug delivery
Total cost: EUR 8 705 549,75
EU contribution: EUR 5 971 173,75